Pfizer (NYSE: PFE) director awarded new phantom stock units
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
SMITH JAMES C reported acquisition or exercise transactions in this Form 4 filing.
Pfizer Inc. director James C. Smith received a grant of 1,664.2010 Phantom Stock Units linked to common stock as deferred board compensation. The units were valued at $27.0400 per unit and increase his phantom stock balance to 170,424.7630 units after the transaction.
Each unit represents one phantom share of Pfizer common stock and includes dividend equivalents. The award is part of deferred director compensation that will be settled in cash or common stock, at Smith’s election, after he retires from the Board of Directors, rather than an open-market purchase.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
SMITH JAMES C
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units | 1,664.201 | $27.04 | $45K |
Holdings After Transaction:
Phantom Stock Units — 170,424.763 shares (Direct)
Footnotes (1)
- Each unit represents one phantom share of common stock. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
Key Figures
Phantom units granted: 1,664.2010 units
Grant valuation price: $27.0400 per unit
Total phantom units after grant: 170,424.7630 units
+1 more
4 metrics
Phantom units granted
1,664.2010 units
Grant of Phantom Stock Units on March 27, 2026
Grant valuation price
$27.0400 per unit
Reference price for Phantom Stock Unit grant
Total phantom units after grant
170,424.7630 units
Director’s Phantom Stock Unit balance following transaction
Underlying common stock linkage
1 unit = 1 share
Each Phantom Stock Unit represents one phantom share of common stock
Key Terms
Phantom Stock Units, deferred director's compensation, dividend equivalents, settled in cash or common stock
4 terms
Phantom Stock Units financial
"security_title: "Phantom Stock Units""
Phantom stock units are company promises that pay a cash or stock-equivalent award tied to the firm’s share price or value growth, but they do not issue actual shares. Think of them as a bonus check that moves with the stock like a mirror rather than handing over an ownership slice. Investors care because these awards can affect a company’s future cash obligations, executive incentives and reported expenses without causing share dilution.
deferred director's compensation financial
"These units represent deferred director's compensation (including dividend equivalents thereon)"
dividend equivalents financial
"including dividend equivalents thereon that are settled in cash or common stock"
Payments tied to employee or contractor equity awards that mirror the cash dividends paid on the company’s stock; they give the holder the same economic benefit as owning the shares without transferring actual shares—often paid in cash or additional award units when the award becomes payable. Investors care because these payments affect a company’s compensation costs, cash flow and potential share dilution, and they signal how management is being rewarded and aligned with shareholders.
settled in cash or common stock financial
"settled in cash or common stock at the director's election following retirement"
FAQ
What insider transaction did Pfizer (PFE) director James C. Smith report?
Pfizer director James C. Smith reported receiving 1,664.2010 Phantom Stock Units as a grant. These units are part of his deferred director compensation and are tied to Pfizer common stock, rather than an open-market stock purchase or sale.
What are the terms of the Phantom Stock Units granted to the Pfizer (PFE) director?
Each Phantom Stock Unit represents one phantom share of Pfizer common stock, valued at $27.0400 per unit. The units accrue dividend equivalents and are settled later in cash or Pfizer common stock, based on the director’s election after retirement from the Board.
How many Phantom Stock Units does the Pfizer (PFE) director hold after this grant?
After receiving 1,664.2010 additional Phantom Stock Units, James C. Smith holds a total of 170,424.7630 phantom units. This reflects his accumulated deferred director compensation tied to Pfizer’s common stock value over time.
When will the Pfizer (PFE) director’s Phantom Stock Units be settled?
The Phantom Stock Units will be settled following James C. Smith’s retirement from Pfizer’s Board of Directors. At that time, he may elect settlement in either cash or Pfizer common stock, as stipulated in the deferred compensation arrangement.